|Previous Section||Index||Home Page|
Mr. Ivan Lewis: The personal social services expenditure return (PSSEX1) is collected by The Information Centre for health and social care, and shows data from local authorities on current expenditure and unit costs on personal social services for adults and children, both nationally and for individual authorities. Expenditure data is presented on a gross and net basis, and is also split between authorities own provision and provision by others. It is also broken down by client groups:
older people (including those with disabilities);
children and family services (including children with disabilities);
learning disabled adults;
physically disabled adults;
mentally ill adults;
asylum seekers; and
other adult services.
|Campaign advertising expenditure for smoking|
|Financial allocations to the NHS for stop smoking services|
|HAZ = Health action zones.|
(1) HAZs only.
(2) 10 million HAZs, 10 million HAs.
(3) £3 million in 2001-02 and 2002-03 for smoking in pregnancy initiative.
In the White Paper Smoking Kills a cost of up to £1.7 billion per year was identified as the cost to the national health service of treating smoking related diseases. This was based on research published by the Health Education Authority in 1997. These documents are available in the Library.
Philip Davies: To ask the Secretary of State for Health what assessment his Department has made of the likely effect of the smoking ban on (a) the number of pubs operating in England and (b) employment in that sector. 
Partial RIAs were included within the Consultation on the Smokefree Elements of the Health Improvement and Protection Bill published in 2005 and in Smoke-free Premises and Vehicles: Consultation on proposed regulations to be made under powers in the Health Bill published in 2006. Both consultation exercises invited stakeholders to provide comments on the partial RIA as well as the proposals in the consultation. Responses from stakeholders assisted the Department in producing the final RIA.
Tim Loughton: To ask the Secretary of State for Health what assessment he has made of the number of children who have (a) died and (b) been brain damaged by volatile substance abuse in each of the last 10 years. 
|Number of children|
Statistics from St. Georges University of London
Dawn Primarolo: A stakeholder group made up of key players in the field, was set up in December 2004 to develop and implement the National Framework for Volatile Substance Abuse. The group was revised in December 2006 to include key departments across Government. It is chaired by the Department.
Department of Health
Department for Education and Skills
Office of the Deputy Prime Minister
Department of Trade and Industry
National Treatment Agency
Local Government OfficeYoung People Lead
Plus the Welsh Assembly and Scottish Executive
National Childrens Bureau
Drug Education Forum
St. Georges University of London
British Aerosols Manufacturing Association
LP Gas Association
Bob Spink: To ask the Secretary of State for Health what assessment he has made of the side-effects of statins; and if he will make a statement on the use of statins under the new National Institute for Health and Clinical Excellence guidelines. 
Ann Keen: The Medicines and Healthcare product Regulatory Agency (MHRA), with independent advice from the Commission on Human Medicines, assesses the balance of risks and benefits of all medicines at the time of initial licensing and throughout their use in clinical practice.
The MHRA reviews new safety information as it emerges, including reports of suspected adverse drug reactions from healthcare professionals and the public, published scientific literature (including clinical trials and epidemiological studies), and periodic safety update reports from pharmaceutical companies. When necessary, the MHRA takes regulatory action to minimise risks and communicate new advice on the safe use of medicines to healthcare professionals and the public.
Statins are generally well tolerated but, as with all medicines, side effects can occur. Serious side-effects, however, are rare. The recognised side effects of licensed medicines are listed in their product information, provided for healthcare professionals. All new medicines are now also required to have patient information leaflets which provide information on how to use the medicine, and on their side effects.
In January 2006 the National Institute for Health and Clinical Excellence published a health technology appraisal of statins which found that they were both clinically and costs effective for prescription to people at a 20 per cent. ten-year risk of developing cardiovascular disease, as well as for patients with established disease. That finding has been repeated in their draft guideline on lipid modification, published for consultation on 27 June.
The Medical Research Council (MRC) is one of the main agencies through which the Government support medical and clinical research. The MRC has funded studies that show cholesterol-lowering statin treatment reduces the risk of heart attacks and strokes by at least one-third as well as lowering the need for arterial surgery, angioplasty and amputations.
In particular the Heart Protection Study (HPS), funded by the MRC and the British Heart Foundation, is the biggest world-wide study of cholesterol lowering therapy. The HPS which reported in July 2002 found significant benefits of statins to people aged over 70 as well as for younger people.
Quality adjusted life years (QALYS) and life-years gained are both measures used by researchers, including the National Institute for Health
and Clinical Excellence (NICE), in evaluating the benefits of treatments and interventions.
In January 2006 the National Institute for Health and Clinical Excellence published a health technology appraisal of statins which found that they were both clinically and cost-effective for prescription to people at a 20 per cent. 10-year risk of developing cardiovascular disease, as well as for patients with established disease. That finding has been repeated in their draft guideline on lipid modification, published for consultation on 27 June.